VALNEVA (EPA:VLA) | WebDisclosure

PRESS RELEASE

published on 08/25/2025 at 07:00, 9 months 28 days ago

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Valneva SE announces FDA's suspension of IXCHIQ® chikungunya vaccine license in the U.S. due to serious adverse events, despite reported cases consistent with clinical trials. Sales impact to be evaluated

FDA Valneva SE Chikungunya Vaccine License Suspension Serious Adverse Events
PRESS RELEASE

published on 08/25/2025 at 07:00, 9 months 28 days ago

Valneva annonce la décision de la FDA de suspendre la licence d’IXCHIQ® aux États-Unis
La FDA suspend la licence d'IXCHIQ® aux États-Unis en raison d'effets indésirables graves liés au chikungunya. Valneva analyse les cas et reste engagée à assurer la sécurité des vaccins

FDA Valneva Suspension Chikungunya IXCHIQ
BRIEF

published on 08/19/2025 at 10:44, 10 months 3 days ago

First Berlin maintient sa recommandation d'achat sur Valneva malgré de solides résultats au deuxième trimestre

Valneva SE Acheter Une Note Vaccin Contre La Maladie De Lyme Résultats Du Deuxième Trimestre Vaccin Contre Le Chikungunya
BRIEF

published on 08/19/2025 at 10:44, 10 months 3 days ago

First Berlin Maintains Buy Rating for Valneva Amid Strong Q2 Results

BUY Rating Q2 Results Valneva SE Lyme Disease Vaccine Chikungunya Vaccine
PRESS RELEASE

published on 08/19/2025 at 10:39, 10 months 3 days ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH has published a research update on Valneva SE, maintaining their BUY rating and EUR 8.10 price target, following better-than-expected Q2/25 results and positive outlook on vaccines

BUY Rating Research Update Q2 Results Valneva SE Vaccine Outlook
BRIEF

published on 08/18/2025 at 07:05, 10 months 4 days ago

Le Vaccin IXCHIQ® de Valneva Autorisé au Canada pour les 12 Ans et Plus

Valneva Santé Canada Autorisation Vaccin Chikungunya
BRIEF

published on 08/18/2025 at 07:05, 10 months 4 days ago

Valneva's IXCHIQ® Vaccine Authorized in Canada for Ages 12 and Older

Health Canada Valneva Vaccine Authorisation Chikungunya
PRESS RELEASE

published on 08/18/2025 at 07:00, 10 months 4 days ago

Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé au Canada pour les personnes âgées de 12 ans et plus
Valneva obtient l'autorisation de Santé Canada pour son vaccin IXCHIQ® contre le chikungunya chez les + de 12 ans. Le vaccin est approuvé en Europe pour les adolescents. Les données de phase 3 montrent une réponse immunitaire durable

Valneva Autorisation Vaccin Chikungunya IXCHIQ®
PRESS RELEASE

published on 08/18/2025 at 07:00, 10 months 4 days ago

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Valneva's Chikungunya Vaccine IXCHIQ® authorized in Canada for individuals aged 12 and older. Health Canada grants marketing authorization for disease prevention

Canada Health Valneva Vaccine Chikungunya
BRIEF

published on 08/12/2025 at 07:05, 10 months 10 days ago

Valneva's Half-Year 2025 Financial Report: Growth and Strategic Moves

Financial Results Strategic Partnerships Revenue Growth Cash Management Regulatory Updates

Published on 06/22/2026 at 21:05, 21 minutes ago

RUM Announces Voting Results From Annual General Meeting of Shareholders
Published on 06/22/2026 at 19:45, 1 hour 41 minutes ago

Trans Canada Gold Appoints Paradigm Drilling Ltd. for Drilling at the Harrison Lake District Scale Gold Project, Drilling to Commence Shortly
Published on 06/22/2026 at 15:58, 5 hours 28 minutes ago

Metallic Minerals Closes Upsized C$10.3 Million Bought Deal LIFE Private Placement
Published on 06/22/2026 at 15:30, 5 hours 56 minutes ago

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
Published on 06/22/2026 at 15:00, 6 hours 26 minutes ago

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program

View all ACCESSWIRE

Published on 06/22/2026 at 21:07, 19 minutes ago

EQS-Adhoc: RWE Aktiengesellschaft: RWE sets placement price for shares from capital measure and raises gross proceeds of 4 billion EUR
Published on 06/22/2026 at 20:50, 36 minutes ago

Ethlabs, Founded by Former Ethereum Foundation Contributors and Funded by Bitmine, Sharplink and Joe Lubin, Launches to Accelerate Ethereum's Institutional Supercycle
Published on 06/22/2026 at 20:32, 53 minutes ago

EQS-Adhoc: Deutsche Konsum Real Estate AG: Daniel Löhken appointed Chief Executive Officer of the Company and Dr Kai Gregor Klinger appointed new Chairman of the Supervisory Board
Published on 06/22/2026 at 19:27, 1 hour 59 minutes ago

Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Published on 06/22/2026 at 18:54, 2 hours 31 minutes ago

EQS-Adhoc: Brenntag SE publishes preliminary operating EBITDA for the second quarter of 2026 and increases its guidance for the financial year 2026

View all EQS

Published on 06/22/2026 at 18:45, 2 hours 41 minutes ago

Governance evolution
Published on 06/22/2026 at 18:45, 2 hours 41 minutes ago

ÉVOLUTION DE LA GOUVERNANCE
Published on 06/22/2026 at 18:16, 3 hours 9 minutes ago

ANTOINE FREY INCREASES HIS STAKE IN FREY
Published on 06/22/2026 at 18:16, 3 hours 9 minutes ago

ANTOINE FREY SE RENFORCE AU CAPITAL DE FREY
Published on 06/22/2026 at 18:00, 3 hours 26 minutes ago

GUILLEMOT CORPORATION : DECES DE M. CLAUDE GUILLEMOT, Président du Groupe GUILLEMOT CORPORATION

View all LES ECHOS COMFI WIRE

News